Century Therapeutics (IPSC) Competitors

Invivyd (NASDAQ:IVVD) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Do insiders & institutionals believe in IVVD or IPSC?

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by company insiders. Comparatively, 6.8% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts recommend IVVD or IPSC?

Invivyd presently has a consensus price target of $11.33, indicating a potential upside of 1,400.90%. Century Therapeutics has a consensus price target of $11.60, indicating a potential upside of 850.82%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is IVVD or IPSC more profitable?

Invivyd has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. Century Therapeutics' return on equity of -61.66% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	N/A	-109.72%	-90.91%
Century Therapeutics	-4,837.73%	-61.66%	-31.78%

Does the media refer more to IVVD or IPSC?

In the previous week, Invivyd had 8 more articles in the media than Century Therapeutics. MarketBeat recorded 13 mentions for Invivyd and 5 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.80 beat Invivyd's score of -0.01 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, IVVD or IPSC?

Invivyd has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Does the MarketBeat Community believe in IVVD or IPSC?

Century Therapeutics received 22 more outperform votes than Invivyd when rated by MarketBeat users. However, 75.00% of users gave Invivyd an outperform vote while only 65.38% of users gave Century Therapeutics an outperform vote.

Company	Underperform	Outperform
Invivyd	Outperform Votes 12 75.00%	Underperform Votes 4 25.00%
Century Therapeutics	Outperform Votes 34 65.38%	Underperform Votes 18 34.62%

Which has preferable earnings & valuation, IVVD or IPSC?

Century Therapeutics has higher revenue and earnings than Invivyd. Century Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$2.26M	39.84	-$198.64M	-$1.96	-0.39
Century Therapeutics	$2.68M	38.65	-$136.67M	-$1.85	-0.66

Summary

Invivyd beats Century Therapeutics on 10 of the 19 factors compared between the two stocks.